Kisspeptin-10 – Research Compound Profile

Kisspeptin-10 – Research Compound Profile

Category: Hormonal Research | Molecular Type: Decapeptide (10 amino acids) | Research Status: Published Human Clinical Trials

This page compiles published research data for qualified researchers. Kisspeptin-10 is sold exclusively as a research compound, is not approved for human use, and this page does not constitute medical advice.

Purchase for Research →

Molecular Overview

Kisspeptin-10 is the minimal biologically active C-terminal decapeptide fragment of the kisspeptin neuropeptide family, consisting of the amino acid sequence Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂ [2][10]. The C-terminal amidation (Phe-NH₂) is essential for receptor binding, consistent with the broader RFamide peptide family, of which kisspeptin is a member. The KISS1 gene was originally identified as a metastasis-suppressor gene at Penn State University in Hershey, Pennsylvania — hence the “KISS” designation, referencing the Hershey Kiss — and encodes a 145-amino acid precursor protein [11]. This precursor is proteolytically cleaved into several bioactive isoforms: kisspeptin-54, -14, -13, and -10, all of which share the identical C-terminal decapeptide sequence and bind the KISS1R receptor with comparable affinity in vitro [10][11].

Despite equivalent receptor affinity, the isoforms exhibit substantially different pharmacokinetic profiles in vivo. Mikkelsen et al. (2009) compared peripherally administered kisspeptin isoforms in a rodent model and documented distinct potency and duration characteristics attributable to differential enzymatic degradation rates [10]. Kisspeptin-10 represents the shortest fragment retaining full agonist activity at KISS1R, making it a valuable tool for studying acute, pulse-like stimulation of the hypothalamic-pituitary-gonadal (HPG) axis in basic research [1][2].

Mechanism of Action

Kisspeptin-10 functions as a potent endogenous agonist of the KISS1R receptor (also designated GPR54), a Gq/11-coupled G protein-coupled receptor densely expressed on gonadotropin-releasing hormone (GnRH) neurons in two key hypothalamic nuclei: the arcuate nucleus and the anteroventral periventricular nucleus (AVPV) [1][12]. The foundational role of this receptor was established by Seminara et al. (2003), who demonstrated that loss-of-function mutations in the GPR54 gene are associated with impaired reproductive axis function in humans, confirming kisspeptin-KISS1R signaling as essential for HPG axis physiology [16]. Conversely, Teles et al. (2008) reported that a gain-of-function KISS1R mutation was associated with altered pubertal timing, further supporting this pathway’s central role in puberty regulation [17].

Upon binding to KISS1R, kisspeptin-10 activates phospholipase C signaling cascades, triggering intracellular calcium mobilization and sustained depolarization of GnRH neurons. Electrophysiological studies by Han et al. (2005) demonstrated that a single application of kisspeptin-10 to GnRH neurons in mouse brain slices produced intense, prolonged depolarization lasting more than 20 minutes [12]. This depolarization drives pulsatile GnRH release into the hypophyseal portal circulation, which in turn stimulates anterior pituitary gonadotroph cells to secrete both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [1].

A defining pharmacokinetic feature of kisspeptin-10 is its extremely short plasma half-life. Jayasena et al. (2011) characterized this half-life through detailed kinetic blood sampling in a human pharmacology study, finding it to be markedly shorter than that of the longer kisspeptin-54 isoform [4][13]. This rapid clearance produces a sharp, pulse-like stimulation of GnRH release rather than a sustained elevation. George et al. (2011) demonstrated in a controlled human pharmacology study that infusion of kisspeptin-10 significantly increased both LH pulse frequency and secretory burst mass per pulse relative to baseline, indicating modulation of the GnRH pulse generator itself [3]. This pulsatile amplification effect distinguishes kisspeptin-10 from direct GnRH administration and may explain why kisspeptin-based stimulation produces a more physiological pattern of gonadotropin release.

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published literature and peptide stability guidelines document the following storage parameters for kisspeptin-10:

• Lyophilized form: Lyophilized kisspeptin-10 is reported as stable for up to 24 months when stored at −20 °C (−4 °F) in a dry, light-protected environment. Sealed vials stored at 2–8 °C maintain stability over shorter periods of approximately 3–6 months [7].
• Reconstituted solution: Once in solution, kisspeptin-10 should be maintained at 2–8 °C (35.6–46.4 °F) and is considered stable for approximately 4 weeks under these conditions [7].
• Freeze-thaw sensitivity: Repeated freeze-thaw cycles have been reported to degrade peptide integrity, and should be avoided for reconstituted preparations [7].
• Light sensitivity: As with most peptides, kisspeptin-10 solutions should be protected from direct light exposure during storage.
• Rapid clearance in vivo: The measured plasma half-life on the order of minutes [4] reflects rapid enzymatic degradation, consistent with the known susceptibility of short, unprotected peptides to serum proteases and aminopeptidases acting on the free N-terminus.
• Surface adsorption: As with many small cationic peptides, kisspeptin-10 has been noted to exhibit non-specific adsorption to glass and some plastic surfaces at low concentration in aqueous buffer, which can reduce apparent recovered concentration in dilute working solutions.

Analytical Characterization

Research-grade kisspeptin-10 lots are characterized using an orthogonal analytical panel. Reverse-phase HPLC establishes chromatographic purity and resolves truncated or deamidated synthesis-related impurities from the intact decapeptide. Electrospray ionization or MALDI mass spectrometry confirms the intact monoisotopic mass, including verification of the C-terminal amidation, which is essential to receptor activity and distinguishes active kisspeptin-10 from an inactive free-acid synthesis byproduct of near-identical mass. A peptide-content assay (versus gross vial mass) accounts for residual counter-ion (typically acetate or trifluoroacetate), water content, and buffer salts. Chiral purity by amino-acid analysis can detect racemization introduced during solid-phase synthesis. Researchers should retain the quality assurance documentation for each lot.

Key Published Research Findings

• Potent LH stimulation in male subjects: In a 2011 Journal of Clinical Endocrinology & Metabolism study, George et al. administered intravenous kisspeptin-10 to healthy men and observed a statistically significant increase in serum LH within 30 minutes of bolus administration [3].

• Testosterone elevation during infusion: In the same study, George et al. reported that continuous kisspeptin-10 infusion over 22.5 hours produced a statistically significant increase in serum testosterone relative to baseline [3].

• Modulation of LH pulsatility: George et al. (2011) further demonstrated that kisspeptin-10 infusion increased both LH pulse frequency and secretory burst mass relative to baseline, consistent with direct modulation of the hypothalamic GnRH pulse generator [3].

• Dose-dependent response: Both George et al. (2011) and Jayasena et al. (2011) documented dose-dependent LH and FSH elevations across a range of intravenous doses, establishing kisspeptin-10 as a titratable experimental LH secretagogue in controlled research settings [3][4].

• Preservation of pituitary responsiveness: George et al. (2011) observed that after prolonged kisspeptin-10 infusion, subjects retained full pituitary GnRH responsiveness to a subsequent GnRH challenge — indicating no pituitary desensitization over the study duration [3].

• Sexual dimorphism in gonadotropin response: Jayasena et al. (2011) reported pronounced sex-dependent variation: male subjects responded to low administered doses, while female subjects in the follicular phase of the menstrual cycle showed no gonadotropin response even at substantially higher circulating kisspeptin levels. Female subjects in the preovulatory phase did respond with significant LH and FSH elevation [4].

• Non-monotonic dose-response relationship: George et al. (2011) noted that a higher bolus dose produced a significantly lower LH response than an intermediate dose, potentially attributable to rapid KISS1R desensitization or off-target activation of the gonadotropin-inhibitory hormone receptor NPFFR1 [3].

• Kisspeptin modulation of sexual brain processing: In a 2022 JAMA Network Open study, Mills et al. administered kisspeptin-54 to women with hypoactive sexual desire disorder in a controlled research setting and observed modulation of brain processing of sexual stimuli, with increased attraction-related responses on functional MRI neuroimaging [14].

• Oocyte maturation in an IVF research protocol: Jayasena et al. (2014) demonstrated that kisspeptin-54 triggered egg maturation in women undergoing in vitro fertilization within a clinical research protocol, with the authors reporting favorable observations regarding ovarian hyperstimulation syndrome (OHSS) risk in that context [18].

Safety Profile in Published Literature

• Acute safety in human studies: George et al. (2011) and Jayasena et al. (2011) reported no adverse events during kisspeptin-10 bolus and infusion studies. Blood pressure, heart rate, peripheral oxygen saturation, liver function, renal function, and electrolytes remained stable throughout all study protocols [3][4].

• Tachyphylaxis with chronic administration of related isoforms: Jayasena et al. (2009) observed that chronic administration of the longer kisspeptin-54 isoform in women with hypothalamic amenorrhea produced tachyphylaxis (diminished gonadotropin response) within approximately two weeks [6]. No comparable chronic administration studies have been published for kisspeptin-10 specifically, and the transferability of this finding across isoforms remains an area of investigation.

• Non-monotonic dose-response (ceiling) effect: George et al. (2011) documented a reduced LH response at a higher dose compared to an intermediate one, suggesting an inverted dose-response at supra-maximal exposures, potentially involving KISS1R desensitization [3].

• Energy deficit interactions: Gordon (2010) reviewed the relationship between energy deficit, hypothalamic amenorrhea, and suppression of KISS1 expression, noting that the kisspeptin-GnRH signaling pathway is sensitive to metabolic status [15].

• Limited chronic toxicology data: Published kisspeptin-10 studies in humans have been limited to acute bolus and short-duration infusion protocols. Long-term safety data from repeated-dose studies in humans are not currently available in the peer-reviewed literature.

Interpretive Limits

Much of the deepest human pharmacology data on this pathway (half-life comparison, chronic tachyphylaxis, IVF oocyte-trigger findings) was generated using the longer kisspeptin-54 isoform rather than kisspeptin-10 itself. Although both isoforms share the identical bioactive C-terminal decapeptide and comparable in vitro receptor affinity, their distinct in vivo clearance rates mean findings from one isoform should not be assumed to transfer quantitatively to the other. Small sample sizes (n=8 in some cohorts) also limit the statistical power of several individual findings cited above.

Regulatory Status

• FDA approval: Kisspeptin-10 has not been approved by the FDA for any indication in humans.
• Clinical trial activity: Kisspeptin peptides (primarily kisspeptin-54) are under active academic and clinical investigation in reproductive endocrinology research, including IVF oocyte maturation and hypothalamic amenorrhea studies. Trials are registered on ClinicalTrials.gov.
• FDA compounding notice: The FDA has noted that compounded drug products containing kisspeptin-10 may pose immunogenicity risk considerations.
• Research-only status: Kisspeptin-10 is sold exclusively as a research compound. It is not intended for human consumption, and all research must comply with applicable laws, regulations, and institutional guidelines.

References

1. Endocrine Reviews (2009) — Oakley AE, Clifton DK, Steiner RA. Kisspeptin Signaling in the Brain. Comprehensive review of kisspeptin’s role as the master regulator of the HPG axis. View Source

2. Journal of Biological Chemistry (2001) — Kotani M, Detheux M, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Identified kisspeptin peptides as KISS1R ligands. View Source

3. Journal of Clinical Endocrinology & Metabolism (2011) — George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. First-in-human kisspeptin-10 dose-response and infusion study. View Source

4. Journal of Clinical Endocrinology & Metabolism (2011) — Jayasena CN, Nijher GMK, Comninos AN, et al. The Effects of Kisspeptin-10 on Reproductive Hormone Release Show Sexual Dimorphism in Humans. Demonstrated sex-dependent responses and kisspeptin-10 pharmacokinetics. View Source

5. Journal of Clinical Endocrinology & Metabolism (2005) — Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 Stimulates the Hypothalamic-Pituitary Gonadal Axis in Human Males. First study of kisspeptin in human males, demonstrating robust LH stimulation. View Source

6. Journal of Clinical Endocrinology & Metabolism (2009) — Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous Injection of Kisspeptin-54 Acutely Stimulates Gonadotropin Secretion in Women with Hypothalamic Amenorrhea, but Chronic Administration Causes Tachyphylaxis. Key study on desensitization. View Source

7. GenScript Peptide Storage Guidelines — Peptide handling and storage best practices: lyophilized peptides stable at −20 °C; reconstituted solutions stable for weeks at 2–8 °C. View Source

10. Regulatory Peptides (2009) — Mikkelsen JD, Bentsen AH, Ansel L, et al. Comparison of the Effects of Peripherally Administered Kisspeptins. Compared pharmacokinetics and potency of kisspeptin-10 vs. longer isoforms. View Source

11. Nature (2001) — Ohtaki T, Shintani Y, Honda S, et al. Metastasis Suppressor Gene KiSS-1 Encodes Peptide Ligand of a G-Protein-Coupled Receptor. Landmark paper identifying kisspeptin as the endogenous ligand of GPR54. View Source

12. Journal of Neuroscience (2005) — Han SK, Gottsch ML, Lee KJ, et al. Activation of Gonadotropin-Releasing Hormone Neurons by Kisspeptin as a Neuroendocrine Switch for the Onset of Puberty. Electrophysiology study demonstrating prolonged GnRH neuron depolarization by kisspeptin-10. View Source

13. Journal of Clinical Endocrinology & Metabolism (2007) — Dhillo WS, Chaudhri OB, Thompson EL, et al. Kisspeptin-54 Stimulates Gonadotropin Release Most Potently During the Preovulatory Phase of the Menstrual Cycle in Women. Established kisspeptin-54 pharmacokinetics and menstrual cycle-dependent sensitivity. View Source

14. JAMA Network Open (2022) — Mills EG, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder. Demonstrated kisspeptin modulates sexual brain processing and attraction responses in HSDD. View Source

15. New England Journal of Medicine (2010) — Gordon CM. Functional Hypothalamic Amenorrhea. Review of energy deficit-induced HPG axis suppression and its relationship to kisspeptin signaling. View Source

16. New England Journal of Medicine (2003) — Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 Gene as a Regulator of Puberty. Foundational paper establishing KISS1R mutations affect reproductive axis function. View Source

17. New England Journal of Medicine (2008) — Teles MG, Bianco SD, Brito VN, et al. A GPR54-Activating Mutation in a Patient with Central Precocious Puberty. Demonstrated that gain-of-function KISS1R mutations are associated with altered pubertal timing, confirming kisspeptin’s essential role in this pathway. View Source

18. Journal of Clinical Investigation (2014) — Jayasena CN, Abbara A, et al. Kisspeptin-54 Triggers Egg Maturation in Women Undergoing In Vitro Fertilization. Reported on kisspeptin as an oocyte maturation trigger in an IVF research protocol. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Kisspeptin-10 is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase Kisspeptin-10 for Research →